Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright

Seaport Therapeutics (NASDAQ:SPTX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 142.13% from the company’s current price.

Several other equities analysts have also recently issued reports on SPTX. Citigroup assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price objective for the company. BNP Paribas Exane cut shares of Seaport Therapeutics to a “market perform” rating in a report on Tuesday, May 26th. Wolfe Research initiated coverage on shares of Seaport Therapeutics in a report on Tuesday, July 7th. They issued a “hold” rating on the stock. Zacks Research upgraded shares of Seaport Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Finally, Leerink Partners assumed coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $35.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Seaport Therapeutics has a consensus rating of “Hold” and an average price target of $38.40.

Seaport Therapeutics Stock Performance

NASDAQ:SPTX opened at $20.65 on Tuesday. The stock has a market capitalization of $1.11 billion and a price-to-earnings ratio of -2.00. The company has a fifty day moving average of $19.36. Seaport Therapeutics has a 12-month low of $14.85 and a 12-month high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last released its earnings results on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.71) by ($1.07).

Insider Buying and Selling at Seaport Therapeutics

In related news, Director Robert J. Hombach bought 13,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was acquired at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the acquisition, the director owned 13,000 shares in the company, valued at approximately $235,820. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.